EK100 appears to have a therapeutic potential for treatment of type 2 diabetes that is associated with hyperlipidemia, by regulating the levels of Glucose transporter type 4 (GLUT4), Phosphoenolpyruvate carboxykinase (PEPCK), Glucose 6-phosphatase (G6Pase), Sterol regulatory element-binding transcription factor 1 (SREBP1c), Sterol regulatory element-binding protein 2 (SREBP2), Apolipoprotein A1 (Apo AI), and AMP-activated protein kinase (AMPK) phosphorylation. Here, SREBF1 is linked to hyperlipidemia.